2 withdrawn, 1 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Withdrawn 2, Completed 1 |
Follow linrodostat: new trials by email Literature Review of linrodostat trials Research Report on linrodostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer BMS-986205, Nivolumab, Chemotherapy - Lung Cancer, Non-Small Cell Lung Cancer | Phase 3 | Withdrawn | Bristol-Myers Squibb | 2018-05-24 | 2018-04-30 | |
| An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck Nivolumab, BMS-986205, Cetuximab - Head and Neck Cancer | Phase 3 | Withdrawn | Bristol-Myers Squibb | 2018-03-28 | 2019-04-18 | |
| An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma BMS-986205, Nivolumab, Placebo - Melanoma, Skin Cancer | Phase 3 | Completed | Bristol-Myers Squibb | 20 | 2017-11-30 | 2021-07-09 |
Carcinoma, Non-Small-Cell Lung (1) · Head and Neck Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Skin Neoplasms (1)
United States (3) · Australia (2) · Canada (2) · Czechia (2) · France (2) · Germany (2) · Greece (2) · Italy (2) · Japan (2) · Spain (2) · Switzerland (2) · Austria (1) · Brazil (1) · Ireland (1) · Mexico (1)
2017 (3)